Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. Its DCVax uses activated dendritic cells to mobilize a patients own immune system to attack their cancer. The company develops DCVax-L, which is under Phase III clinical trials for glioblastoma multiforme brain cancer and ovarian cancer, and for other cancers in situations, which the patient has their tumor surgically removed as part of standard of care; DCVax-Direct that is under Phase I/II clinical for solid tumor cancers; and DCVax-Prostate, which is under Phase III clinical trial for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
May 1, 2018
RegMed Investors’ (RMi) closing bell; hanging with a different crowd
April 30, 2018
RegMed Investors’ (RMi) closing bell; finally April is over
April 28, 2018
RegMed Investors’ (RMi) closing bell; enough of being oversold
April 26, 2018
RegMed Investors’ (RMi) closing bell; a rally finish
April 25, 2018
RegMed Investors’ (RMi) closing bell; equities flip, flop while playing catch-up
April 24, 2018
RegMed Investors’ (RMi) closing bell; an embattled sector
April 23, 2018
RegMed Investors’ (RMi) closing bell; trading is very thin
April 23, 2018
RegMed Investors’ (RMi) pre-open: volatility has hurt
April 20, 2018
RegMed Investors’ (RMi) closing bell; the sector and market got pummeled
35 companies, 1 interpreter!
Insight, foresight and recommendation
Northwest Bio (NWBO) – What investor can stand the constacy of dilution and its consistent "problem" with perception and sentiment having watched it waste away ... stay away.
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors